China’s Policies To Promote Life Science Industry
This article was originally published in PharmAsia News
National Development and Reform Commission officials revealed at a recent China Bioindustry Convention that it and 19 other departments have jointly drafted policies on boosting China bioindustry development. Pending approval from the State Council, the policies revolve around incubating life sciences firms at initial start-up phase and developing those in the expansion stage. The document proposes measures for the industrial structure, investment and fundraising, finance and tax, market environment, talent and biological safety to boost the industry. Meanwhile, the draft also takes into consideration practical application to ensure implementation. (Click here for more - Chinese Language)
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.